Show simple item record

Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorSloane, Robert
dc.contributor.authorPriest, Lynsey
dc.contributor.authorLancashire, Lee J
dc.contributor.authorHou, Jian-Mei
dc.contributor.authorGreystoke, Alastair
dc.contributor.authorWard, Timothy H
dc.contributor.authorFerraldeschi, Roberta
dc.contributor.authorHughes, Andrew
dc.contributor.authorClack, Glen
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorDive, Caroline
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2011-07-12T12:12:31Z
dc.date.available2011-07-12T12:12:31Z
dc.date.issued2011-04-20
dc.identifier.citationEvaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. 2011, 29 (12):1556-63 J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid21422424
dc.identifier.doi10.1200/JCO.2010.28.7045
dc.identifier.urihttp://hdl.handle.net/10541/135882
dc.description.abstractLung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCell Adhesion Molecules
dc.subject.meshDisease-Free Survival
dc.subject.meshEngland
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunomagnetic Separation
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshNeoplastic Cells, Circulating
dc.subject.meshPredictive Value of Tests
dc.subject.meshProportional Hazards Models
dc.subject.meshProspective Studies
dc.subject.meshRisk Assessment
dc.subject.meshRisk Factors
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.subject.meshTumor Markers, Biological
dc.titleEvaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom.en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractLung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy.


This item appears in the following Collection(s)

Show simple item record